ArticleEndocrine2025
"Cardiometabolic outpatient clinics: evidence from collaborative academic tertiary centers-research article".
Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Barriers to long-term follow-up among patients in cardiovascular-metabolic clinics: a qualitative study based on the COM-B model.BMC health services research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePatients with type 2 diabetes mellitus (T2DM) exhibit high morbidity and mortality despite research progress. The aim of this study was to assess the efficacy of multidisciplinary cardiometabolic outpatient clinics in medical treatment of T2DM outpatients.
methodsA prospective, cohort study of 200 T2DM patients attending cardiometabolic, tertiary, outpatient clinics of “Sotiria” Chest Disease Hospital and Attikon Hospital was conducted. Patients underwent structured clinical evaluation at each visit by both Diabetologists and Cardiologists including cardiovascular risk assessment, lifestyle change recommendations and optimization of medical treatment based on ESC Guidelines.
resultsOur population comprised by 76% males (mean age: 62 ± 10 years; median T2DM duration: 6.5 years); also, hypertension (75%), dyslipidaemia (79%) and coronary artery disease (CAD) (45%) were the most common comorbidities. Only 21% of very high-risk patients had LDL cholesterol < 55 mg/dL at baseline and a small percentage received the novel antidiabetic agents. During follow-up (median: 5 months), significant improvement of BMI (33.3 ± 6.2 to 32.1 ± 6.05 kg/m², p < 0.001), HbA1c (7.85 ± 1.73% to 6.86 ± 1.05%, p < 0.001) and LDL cholesterol (86.7 ± 33.3 mg/dL to 60.4 ± 28.6 mg/dL, p < 0.001) occurred. At follow-up, 71.5% of patients received GLP-1 RA, 56% SGLT2i and 85.5% statin; 8.5% were up-titrated to high-intensity statin and 27.5% received statin plus ezetimibe. Interestingly, 78% of very-high CVD risk patients achieved LDL cholesterol < 55 mg/dL at follow-up. Comprehensive screening revealed previously unrecognized CAD, heart failure and peripheral artery disease in 31%, 13% and 8% of patients, respectively.
conclusionsCardiometabolic outpatient clinics improve cardiovascular risk factor profile, adherence to the Guidelines and facilitate early detection of cardiovascular complications in T2DM patients.
Indexed as
Identifiers
41091292What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.